Peptides do not have a single common profile of side effects. The risk depends on the specific molecule, its biological target, the formulation, the route of exposure, the size and duration of exposure, the quality of the product, and the characteristics of the person being studied. A cosmetic cream containing peptides, a metabolically active drug approved for commercial use, and an experimental injection preparation are therefore three completely different safety issues.
This distinction is fundamental because the term „peptide” describes a broad chemical category, not a single drug or a single type of biological action. Two substances can contain peptide bonds while acting on completely different receptors, reaching other tissues, being administered through different routes, and causing completely different adverse effects.
Well-controlled studies clearly show why this particular effect is important. In studies of bremelanotide, nausea, skin redness, and headache occurred more frequently than in the placebo group, while in studies of tirzepatide, gastrointestinal adverse effects were predominant. In contrast, in a small study of a locally applied tetrapeptide, no adverse effects were observed over a limited observation period.[1][2][3]
These results refer to specific interventions that were actually studied. They cannot be combined into a single general conclusion that peptides as a whole group are „safe” or „unsafe”.
Safety assessment therefore requires an answer to several separate questions. What specific molecule is being analyzed? What formulation has been tested? By what route was it administered? What population was it administered to? How long were the participants observed? What adverse effects occurred compared to the control group? Was the product under study properly characterized? What important risks remain unknown because sufficiently long studies were not conducted or specific populations were not studied?
In this article, we explain how to interpret known adverse reactions, uncertain risks, results of quality product studies, interactions, and gaps in data regarding particularly sensitive groups. This is educational material, not a full safety profile for each peptide or peptide-related drug. The current examples, sourced from official sources, used during the preparation of this review, were verified on September 20, 2026.
Why is the safety of peptides dependent on the specific substance and the route of exposure?
The first principle when assessing the safety of peptides is that the risk applies to a specific intervention, not to the word „peptide” itself.
The biological target of the molecule, the route of administration, the formulation, the magnitude of exposure, and the quality of the manufacturing process can all influence both the type of possible adverse effects and their clinical significance.
A specific molecule determines the type of biological action
Peptides differ in their amino acid sequence, length, structure, chemical modifications, stability, receptor affinity, pharmacokinetics, and biological targets.
One peptide may affect signaling related to the reproductive system. Another may affect metabolic regulation. Another may be a component of a cosmetic product intended primarily for topical use on the skin.
The expected side effects will therefore be different.
The undesirable effect may result from action on the intended pharmacological target. It may also be related to another biological action, excessive exposure, the formulation component, contamination, a degradation product, or an interaction with another drug.
The fact that a peptide resembles a naturally occurring substance or has been derived from it does not mean that a product administered externally is harmless.
The body produces its own signaling molecules within precisely regulated physiological systems. An externally administered preparation can lead to a different concentration, longer exposure, different tissue distribution, or a different pattern of receptor activation.
A reliable safety assessment must therefore begin with a precise determination of the identity of the molecule and the product.
Terms such as „wellness peptide”, „regenerative peptide”, „anti-aging peptide”, „natural peptide” or „research peptide” do not provide sufficient information to determine the safety profile.
A good example of this problem are the claims regarding hormones. As we show more extensively in the article about peptides and testosterone, Even peptides acting within the reproductive system can lead to very different effects depending on the molecule, the receptor, and the time of exposure.
The route of administration changes the exposure and the type of significant risk
Topical, oral, injectable and injection-ready products encounter various biological barriers.
Consequently, they can lead to very different patterns of exposure.
Data obtained for one reporting route should not be automatically transferred to another.
A study of a product applied to the skin may, for example, provide useful information regarding irritation or local tolerance of a specific formulation. However, it does not automatically confirm the safety of systemic, reproductive, cardiovascular, metabolic, or long-term effects.
Similarly, a study of the oral preparation does not allow one to independently conclude that a similarly named injectable preparation provides the same exposure or has an identical risk profile.
The wording itself is also important.
The delivery technology, preservatives, buffers, excipients, concentration, stability, and other properties are part of the actual intervention.
The route of administration also affects which issues related to product quality become particularly important.
In the case of preparations intended for parenteral administration, particular importance is given to microbiological contamination and endotoxins, as natural protective barriers of the gastrointestinal tract or intact skin are bypassed.
Even here, however, the laboratory result must be interpreted in accordance with what was actually examined. No single analytical test confirms all aspects of the product's quality and its safety for humans.
Cosmetic tolerance applies to the finished formulation
Studies of peptides used in cosmetics clearly show why safety must be interpreted in relation to the specific formulation.
In a 12-week study of an eye-area preparation containing tetrapeptide-68, involving 25 women, no adverse reactions were observed during the observation period.[3]
This is useful information regarding tolerance.
However, it applies to a specific prepared formulation, the population being studied, the duration of the study, and the study conditions.
It does not prove that every product containing tetrapeptide-68 will produce identical results.
This does not mean, however, that every cosmetic containing peptides is free from the risk of irritation.
Cosmetics contain many ingredients.
Aromatics, preservatives, solvents, plant ingredients, surfactants, and other formulation components can contribute to irritation or allergic reactions. The FDA’s information on cosmetic allergens also emphasizes the importance of the entire product composition and individual susceptibility. [4]
Therefore, if a skin reaction occurs after applying a cream containing a peptide, the mere presence of the peptide does not prove that it is the cause of the reaction.
However, it is also not advisable to assume the opposite.
The mere presence of the peptide does not make the other ingredients less important, nor does the finished product automatically be gentle on the skin.
Safety and tolerance apply to the entire formulation and to the specific person who comes into contact with it.
We discuss more about interpreting cosmetic tests in materials related to this topic. peptides in the eye area and peptides for sensitive and acne-prone skin.
Medicines that are allowed to be marketed have a certain, but not zero, risk.
The marketing of a medicine does not mean that the product is free of side effects.
This means that it has been subjected to a specific regulatory assessment for specific uses, populations, formulations, and conditions of use.
Therefore, benefits and clinically significant risks can occur simultaneously.
An example is bremelanotide. Current information regarding the prescribing of this drug in the United States includes cardiovascular system-related restrictions, transient changes in blood pressure, and specific interaction issues.[5]
These are important safety information regarding bremelanotide.
However, they should not be transformed into a general characteristic of all peptides.
Similarly, the adverse reactions identified for another peptide drug approved for marketing are primarily related to that specific drug and the conditions in which it was tested.
Therefore, when evaluating a single drug, up-to-date, complete information regarding the specific product remains important.
The general educational article may explain the categories of safety evidence, but it does not replace information about contraindications, warnings, precautions, interactions, or individual clinical assessment.
This same biological effect can have different meanings in different situations.
Safety cannot always be evaluated by classifying a single biological change as simply „good” or „bad.”.
The purpose of the intervention is important.
Hormonal changes desired in one clinical context may be undesirable in another.
For example, in acylin studies, testosterone suppression was a targeted pharmacodynamic result.[6]
This does not mean that every hormonal change should be considered harmful.
It does, however, show that biological activity should be interpreted in relation to the purpose of the study and the participant's situation.
Therefore, it is not enough to ask whether the peptide is biologically active.
Most of the pharmacologically interesting peptides are biologically active by definition.
The more important question is: is the overall balance of benefits, adverse effects, uncertainties, and available alternatives acceptable for a specific indication and specific population?
Reported adverse reactions and unknown risk are two different concepts
Safety data include both events actually observed by researchers and risks that available studies were unable to adequately assess.
These two categories should not be confused with each other.
A documented adverse event and an unknown long-term risk are two different types of information.
Similarly, the absence of an observed event does not prove that it cannot occur.
An adverse event does not automatically mean a causal relationship.
An adverse event is an adverse event recorded during an examination or after a specific exposure.
The very fact that it occurred after intervention has not yet proven that it was caused by it.
Symptoms may occur in a participant as a result of the underlying disease, another medication, an independent infection or illness, a natural population risk, or a simple coincidence of circumstances.
A suspected adverse effect means that a causal relationship is considered possible, but even then the strength of the evidence can be different.
Researchers and regulatory authorities may take into account, among other things, the time of occurrence of the event, biological plausibility, recurrence, dependence on dose or exposure, differences compared to the control group, and other possible explanations.
Case reports are valuable because they can reveal atypical patterns that require further investigation.
However, a single case usually does not allow us to determine how often the given event occurs.
It also does not prove that every similar symptom that appears after exposure has the same cause.
The safety signal should therefore not be automatically dismissed or presented as final proof without the relevant data.
Does the occurrence of an adverse event prove that a peptide caused it?
Not always. An event occurring after exposure may also have other causes. When assessing the causal relationship, the time of occurrence, biological plausibility, co-existing diseases, other medications taken, recurrence, and differences from the control group are taken into account among other things. Controlled studies, such as studies of bremelanotide, help determine whether specific events occur more frequently after the intervention being studied is applied. [1]
Controlled studies provide an important reference point
Randomized controlled trials provide a control group that makes it easier to assess whether certain events occur more frequently after the intervention is applied than without it.
For example, if the headache occurs in both the active and placebo groups, it is important to compare the frequency of its occurrence.
The same principle applies to gastrointestinal symptoms, nausea, skin redness, discontinuation of treatment, and other outcomes.
In phase III studies of bremelanotide, nausea, skin redness, and headaches occurred more frequently after bremelanotide than with placebo.[1]
In a tirzepatide study on obesity, adverse reactions and discontinuation of treatment were reported in parallel with the efficacy results, and gastrointestinal adverse reactions occurred particularly frequently.[2]
Such controlled comparisons are usually more useful in assessing common treatment-related events than individual user reports.
Even large randomized studies have limitations, however.
Rare events may require exposure of a significantly larger number of people before it is possible to determine their frequency.
The delayed effects may not appear during the course of the study.
People excluded from the study may have a different risk profile.
Controlled studies therefore provide important safety data, but they do not always answer all possible questions.
The severity and seriousness of the incident do not mean the same thing
In safety reporting, the concepts of severity and seriousness have different meanings.
Severity is usually described as the intensity of the event, for example as mild, moderate or severe.
Severity refers to the consequences specified in safety reporting systems, such as hospitalization, life-threatening conditions, or other medically significant outcomes.
The symptom can therefore be very intense and unpleasant, and at the same time it does not meet the regulatory definition of a serious adverse event.
On the other hand, the event can have serious medical significance, even if its initial symptoms do not seem particularly dramatic.
The summaries of the studies should maintain this distinction.
Similarly, the information that the majority of adverse reactions were mild or moderate should not be automatically interpreted as „no significant risk”.
A small number of severe or serious events, cases of treatment discontinuation, contraindications and restrictions may still have significant clinical significance.
The absence of observed adverse effects does not mean zero risk
The size of the study strongly influences what safety conclusions can be drawn from it.
If only 25 carefully selected participants were observed for 12 weeks, rare events may simply not occur in such a small sample.
This is well demonstrated by the aforementioned study of the cosmetic tetrapeptide [3].
The absence of observed adverse reactions is useful information regarding the formulation and participants being studied.
However, it does not constitute a universal safety certificate.
The study does not show what would happen to thousands of people with other skin conditions after prolonged exposure or when using another formulation.
This principle is even more important in the case of experimental substances that act systemically.
An early-phase study with a small number of carefully selected participants can provide valuable preliminary information regarding tolerability, while leaving significant uncertainties regarding repeated exposure, rare events, long-term effects, and groups excluded from the study.
„No events have been observed” and „such an event cannot occur” are, from a scientific point of view, two completely different statements.
Does the absence of reported adverse reactions mean zero risk?
No. The size and length of the study determine how much can actually be said about the risk. The absence of observed reactions in 25 participants of the local tetrapptide study is useful but limited information. [3] Rare or delayed events could remain undetected. The correct conclusion should therefore state what was observed, in how many people and for how long.
Longer observation can also have limitations
A longer observation period is usually valuable, but the design of the study still needs to be taken into account.
People who have completed the earlier part of the study and were ready and qualified to continue participating often end up in open-ended, extended studies.
This can lead to selection.
People who previously experienced poorly tolerated effects could already resign.
Participants continuing the study can therefore constitute a group that tolerates the intervention better than all those initially exposed.
In an extended study of bremelanotide, 684 people were enrolled for further observation, and 272 completed it. The researchers did not find any new safety signal. [7]
This provides useful long-term data.
Limitations regarding eligibility, loss of participants, and the absence of a continuous comparison group, however, affect the scope of possible conclusions.
This does not invalidate the prolonged study.
It only specifies what such an examination can actually reveal.
Longer observation improves the quality of the data, but it does not necessarily resolve all questions regarding rare or delayed adverse reactions.
Safety signals require investigation, not over-exaggeration or ignoring them
The safety signal may appear even when the substance has convincing biological justification.
A randomized trial of ibutamoren in elderly people recovering from hip fracture was prematurely terminated due to a signal regarding congestive heart failure.[8]
Ibutamoren is a non-peptidic compound, although it often appears in discussions alongside peptides. Therefore, the result should not be presented as a risk for the entire class of peptides.
Its significance in this context is methodological.
The study shows that an attractive mechanism of action, beneficial biomarkers, or convincing theoretical justification are not evidence of clinical safety.
It also shows why the result must remain related to the population being studied.
The safety signal observed in older people after a hip fracture cannot simply be translated into an accurate risk for healthy young adults or other populations.
The correct response to a safety signal is an accurate analysis of the specific intervention, the population, the event, and the supporting data.
Product quality and contamination are separate safety issues
Clinical pharmacology and product quality are related, but they do not mean the same thing.
Even if the biological activity of the molecule is well understood, a poorly manufactured, incorrectly labeled, or contaminated product can introduce additional risks that were not present in clinical studies.
Clinical data suggest that the intervention under investigation is identifiable.
The safety results of the clinical trial relate to the product that was actually administered to the participants.
Another product sold under the same ingredient name may differ in active substance content, concentration, impurities, excipients, degree of degradation, stability, or microbiological quality.
The authenticity of the product is therefore a separate issue from pharmacology, which is called the molecule.
The original approved drug and the counterfeit product bearing the same name cannot be considered equivalent exposures.
The same principle applies to experimental materials.
The label containing the name of the peptide does not in itself prove that the vial actually contains that molecule.
The seller's declaration does not confirm the amount of the substance.
The term „research use only” does not confirm the identity, purity, sterility, stability, or suitability for human use.
The quality of the product therefore requires its own proof.
The study of online shopping revealed specific quality issues
An example of direct quality analysis of products is the study of semaglutide sold over the internet without a prescription.
Investigators conducted targeted purchases at six illegal online pharmacies.
Three products arrived in vials, while three alleged products in bottles were not delivered.
Laboratory analysis of the received vials showed, among other things, the presence of substances exceeding the values declared on the labels and the presence of endotoxins.[9]
No live microorganisms were detected in the samples tested.
However, this did not invalidate the separate result regarding endotoxins.
This distinction is important because different quality studies address different questions.
The study included a small, intentionally selected group of sellers.
Therefore, it does not allow for determining the frequency of such problems in all online pharmacies, all prescription drugs, all products containing semaglutide, or across the entire peptide market.
Its significance is narrower, but still important: direct laboratory studies have shown that specific quality problems may occur in products obtained from the sources examined.
Identity, quantity, purity, microbiological quality, endotoxins and stability are different measurements
The quality of a product cannot be reduced to a single laboratory value.
This identity test answers the question of whether the detected material corresponds to the expected substance. It does not independently confirm the correct quantity, the absence of impurities, sterility, stability, or clinical usefulness.
The quantitative analysis determines how much active substance is present in the sample. It does not prove the absence of impurities.
Chromatographic purity determines the proportion of material recognized by the method used as the main substance compared to the detected impurities. It does not independently confirm sterility, endotoxin levels, the exact amount of the substance, or the absence of all possible impurities.
Microbiological tests check for the presence of microorganisms under specific test conditions. A negative result does not prove the absence of endotoxins or chemical contaminants.
The endotoxin test assesses the presence of bacterial endotoxins within the limits of the method used. It does not confirm the identity of the product, the correct concentration, efficacy, or the absence of all other impurities.
Stability studies determine whether the defined product characteristics remain within the specifications over time and under specified storage conditions. The stability data alone do not establish a complete safety profile for humans.
Therefore, a high percentage obtained in one analytical test should not be considered as proof of compliance with all other quality requirements.
The method, sample, batch of product, laboratory procedure, and the way the result is interpreted are all important.
Does 99% purity mean that the peptide product is safe?
No. Purity is the result of a specific analytical measurement. It does not independently confirm the correct quantity, complete identity, sterility, endotoxin levels, stability, absence of all impurities, or clinical usefulness. The study of semaglutide online products revealed several different types of quality issues requiring different analytical methods. [9] The purity result is therefore only one element of the product’s characteristics.
Endotoxins and live bacteria do not mean the same thing
The microbiological terminology can be confusing.
Endotoxins are associated with components of certain bacteria.
The product may therefore raise concerns regarding endotoxins even when no live microorganisms were detected in the microbiological test conducted.
Therefore, the statement „nothing has grown in the breeding process” does not mean that the product meets all microbiological safety requirements.
A study of semaglutide products purchased online directly showed this difference in the samples analyzed.[9]
Similarly, chromatographic purity does not answer the question regarding endotoxins.
The product can appear to have a high chromatographic purity rating, while still requiring a separate microbiological quality assessment, endotoxins, quantity, stability, and other parameters.
Each analytical test has its own specific purpose.
Does the negative result of the microbiological test rule out the presence of endotoxins?
No. The testing of live microorganisms and the detection of bacterial endotoxins address two different questions. In the study of semaglutide products purchased online, endotoxins were detected in the samples obtained, despite the absence of live microorganisms in the microbiological tests used. [9] A negative result from one test cannot therefore substitute for the detection of endotoxins or other required quality tests.
Pollutions, degradation and aggregation of peptides may be significant
The conditions of production and storage can change the properties of peptide preparations.
Degradation, chemical modifications, aggregation, and the formation or accumulation of pollutants are possible, among other things.
These changes can affect the material's properties.
Some pollutants or altered forms of the molecule may also complicate the assessment of the immune response.
The FDA’s information regarding the risks associated with prescription drugs indicates problems with the characteristics and potential immunogenicity of several specific substances, as well as significant data gaps regarding safety in humans.[10]
These concerns should be interpreted in relation to the specific substance and route of administration.
They do not prove that every peptide preparation causes an immune reaction.
At the same time, they do not allow the opposite simplification that peptides must be automatically harmless only because amino acids are natural components of the body.
The safety of a peptide preparation depends on a much larger number of factors than the amino acids it can ultimately be broken down into.
The term „research use only” is not a human safety assessment
The label „research use only” does not imply that the product has been evaluated for human use.
It does not confirm the appropriate route of administration.
It does not confirm the validated pharmaceutical quality.
It does not confirm clinical effectiveness.
It does not establish an acceptable risk-benefit ratio.
The FDA described problems with products advertised using research terminology, while at the same time being offered for human use.[11]
Therefore, terms related to research use should not be interpreted as regulatory authorization or assurance of clinical safety.
The analytical certificate issued by an independent laboratory is another type of proof.
It can provide useful information about the specific sample being examined and the measurements performed.
However, it is not a clinical approval.
Its significance depends on the methods used, the parameters actually examined, and the possibility of reliably linking the sample to a specific product or batch.
Does the term „research use only” mean that the product is safe for humans?
No. Such labeling does not confirm clinical utility, validated pharmaceutical quality, regulatory approval, or an acceptable benefit-risk ratio in humans. The FDA described problems with products advertised using research terminology while being offered to people.[11] The label itself does not replace data regarding product quality or clinical studies.
Interactions and particularly sensitive populations require separate data
Safety data obtained in healthy adult individuals may not describe the risk in individuals with co-morbid conditions, pregnant women, breastfeeding women, children, the elderly, or patients taking other medications concurrently.
These groups often require separate examinations.
Drug interactions do not necessarily result from action on the same receptor
Two drugs do not have to act on the same receptor for an interaction to occur between them.
One intervention can change the absorption, distribution, metabolism, or elimination of another drug.
It can also enhance a specific physiological effect without changing the concentration of the second drug.
A documented example is bremelanotide.
Current product information indicates a delay in stomach emptying and a reduction in exposure to some oral medications, including a specific interaction with naltrexone.[5]
This is a characteristic interaction of bremelanotide, and not a general principle stating that every peptide delays stomach emptying or interacts with the same drugs.
The broader conclusion is that connections that have not been tested should not be automatically considered safe simply because the individual components have been previously discussed or tested separately.
After the substances are combined, their joint use becomes a separate research question.
Co-existing diseases can change the risk context
Disorders of kidney or liver function, cardiovascular diseases, metabolic disorders and other clinical conditions can affect the way the drug is metabolized or tolerated.
The significance of these factors depends on the specific molecule.
A clinical trial conducted in healthy adults may intentionally exclude individuals at increased risk of certain complications.
Good tolerance in such a selected group cannot therefore be automatically transferred to individuals who were excluded from the study.
The study of ibutamoren after a hip fracture again shows how the assessment of a specific clinical population can reveal a safety profile that differs from expectations based on the mechanism of action or data from other populations.[8]
Therefore, safety information should always be linked to the characteristics of the participants being studied.
Pregnancy requires data on specific results
The safety of pregnancy cannot be inferred based on the natural origin of the substance, its peptide structure, or the experiences of people who are not pregnant.
The studies must take into account the duration of exposure, the characteristics of the mother, underlying diseases, pregnancy outcomes, fetal and neonatal outcomes, and statistical precision.
A prospective cohort study on exposure to GLP-1 receptor agonists in early pregnancy yielded reassuring results with respect to the endpoints examined, but remained limited by the sample size and the observational nature of the project.[12]
This type of study can provide useful data involving human participants.
However, it does not confirm the complete safety of every particle, dose, formulation, exposure period, or every stage of pregnancy.
Therefore, a reassuring result should remain reassuring within the limits of the data actually obtained and not be transformed into a general safety declaration.
Topics related to physiology, hormones, and specific populations are also discussed in the article about peptides for women.
Breastfeeding requires a separate assessment
Pregnancy and breastfeeding are not the same safety issue.
Studies of lactation may require assessment of the absorption of substances into the female’s milk, their absorption by the infant, the child’s health outcomes, the impact on milk production, the mother’s nutrition, and her health status.
Measuring the concentration of the drug in a small number of milk samples only answers part of these questions.
In a small semaglutide study involving eight women, no drug was detected in the analyzed milk samples, but the authors also pointed out unresolved issues regarding long-term outcomes and nutrition.[13]
The analytical result is informative.
However, it should not be generalized automatically to every peptide, every formulation, every infant age, or every stage of lactation.
A reassuring result regarding absorption into milk may be valuable, but it does not constitute a complete assessment of safety for the mother and child.
Children and other underrepresented groups require special caution.
Data on safety in adults do not automatically confirm pediatric safety.
Children differ in terms of development, physiology, the nature of diseases, and outcomes requiring observation.
Older people may also be underrepresented in clinical trials, especially if they have multiple diseases or are taking numerous medications at the same time.
The same applies to people with significant kidney, liver, cardiovascular, hormonal or immunological diseases.
The safety summary should indicate these limitations, rather than treating the population included in the study as representative of everyone.
If an adverse event is suspected in a particular individual, exposure during pregnancy or breastfeeding, or a possible interaction, the assessment requires knowledge of the actual product and the clinical circumstances.
General statements regarding „peptides” are not precise enough to determine the cause or appropriate medical treatment.
How should evidence regarding the safety of peptides be evaluated?
A useful security assessment should start with a specific intervention and only then move on to broader conclusions, not vice versa.
First, the identity and significance of the data must be determined.
The first questions are simple but crucial.
What exact substance was being tested?
What ready-made preparation was used?
What route was it administered by?
What population did he receive it from?
How long did the exposure and observation last?
Does the population being studied resemble the group to which the evaluated safety claim applies?
The next step is to determine the type of evidence.
A randomized clinical trial, an observational cohort, a case report, a regulatory notice, a laboratory quality study, and the user's personal experience all answer different questions.
Laboratory testing can reveal a product defect without simultaneously measuring its clinical consequences.
A clinical study may describe adverse reactions, but it does not guarantee that the unrelated commercial product has the same identity and quality of production.
The type of proof must therefore correspond to the claim it is intended to confirm.
Attention should be paid to the number of participants and the length of the observation period
The number of adverse reactions is difficult to interpret without information about how many people were exposed and how long the exposure lasted.
Ten reports among 50 participants mean something completely different than ten cases among 50,000 people.
Time also matters.
Ten events during a few days of observation and ten events over several years represent different exposure conditions.
Systems for spontaneous reporting of adverse reactions often lack a reliable denominator.
Reports may also be incomplete, duplicative, fueled by media interest, or dependent on differences in reporting behaviors.
Therefore, the numbers of reports themselves should not be automatically converted into the incidence rate.
They are, however, particularly useful in identifying potential safety signals that require further investigation.
Clinical studies should, as far as possible, provide the number of people exposed, adverse reactions in individual groups, serious events, withdrawals, cases of discontinuation of treatment, and the method of conducting further follow-up.
Such information says much more than just the statement that the product was „well-tolerated”.
The risk should be analyzed along with the benefits
Safety and effectiveness should not be treated as two completely independent stories.
The positive efficacy result does not eliminate the adverse effects.
On the other hand, the mere occurrence of adverse reactions does not determine whether the drug has an acceptable benefit-risk ratio in a confirmed clinical indication.
Studies of bremelanotide and tirzepatide reported both efficacy and tolerability results.[1][2]
A balanced summary of the evidence should preserve both sides.
The context becomes particularly important when the proposed use has not been confirmed.
Accepting known risk in the case of a drug with documented benefits in a clinically appropriate population is a different matter than accepting the same or unknown risk in an application devoid of proven benefits.
Uncertainty regarding effectiveness is therefore also important when interpreting safety.
It is necessary to distinguish between known risks, safety signals, and missing information.
Different patterns of evidence allow for different conclusions.
The repeated increase in the frequency of a specific event in controlled studies may indicate a risk associated with the intervention in a specific population and under specific conditions.
The description of a case or a signal from the spontaneous reporting system may indicate a potential association that requires further evaluation, but it does not necessarily confirm a causal relationship or a frequency of occurrence.
The results of a toxicology study in animals provide important preclinical information, but caution should be exercised when extrapolating to human risk.
The absence of adverse effects in a small, short study means that they were not observed under these conditions. It does not prove a zero risk.
If there are no adequate human studies, the proper conclusion is that the risk is insufficiently characterized, not that the intervention has been shown to be safe.
Product quality defects create another category of problem because they mean that the actual exposure may differ from the intervention described in clinical studies.
The lack of data should therefore not be presented as reassuring evidence.
At the same time, uncertainty should not be presented as proof of harm if there is no data to confirm a causal relationship.
What should a reliable peptide safety proposal look like?
A scientifically justified safety proposal should indicate a specific intervention.
It should describe the observed adverse reactions.
It should indicate the population under study and the route of exposure.
It should take into account the duration of the exposure and observation.
He should take the comparative group into account.
It should indicate significant exclusions and areas of uncertainty.
He should also distinguish between pharmacological safety and problems related to product quality.
First of all, it should not issue a single verdict regarding the entire category of peptides.
Statements such as „peptides are safe because they are natural” and „peptides are dangerous because one peptide caused a specific adverse effect” are based on the same mistake: treating a broad chemical category as a single intervention.
Natural origin, percentage of purity, availability in sales, the term „research use only” or the absence of reported adverse reactions cannot replace evidence regarding a specific intervention.
The strongest assessment combines the actual product with appropriate qualitative data, proper human-based studies, current information regarding the specific product, and clearly identified areas of uncertainty.
Frequently asked questions about the side effects and safety of peptides
Are natural peptides always safe?
No. The natural occurrence of the substance does not confirm the safety of an externally administered preparation, the route of administration, the concentration, formulation, or the duration of exposure. The body naturally regulates the naturally occurring signaling molecules within complex physiological systems, whereas external administration can create a completely different pattern of exposure. The FDA also pointed to a lack of information regarding the safety of certain specific peptide preparations.[10]
Do all peptides cause the same side effects?
No. Individual peptide drugs and formulations target different biological targets and lead to different exposure patterns. Bremelanotide, tirzepatide, and the topical tetrapeptide have different safety testing results.[1][2][3] The results should be attributed to specific interventions rather than creating a single universal list of „peptide side effects”.
Does a single study of defective products describe the entire peptide market?
No. The study of semaglutide products included selected retailers and only three products delivered in vials. [9] It directly showed quality issues in these specific samples, but does not allow to determine how often similar problems occur in all retailers, in prescription products, authorized products, or across the peptide market. Its significance lies in showing possible real ways in which quality defects occur.
Can a peptide cream cause a reaction due to another ingredient?
Yes. The finished product contains significantly more than the main active ingredient. Fragrances, preservatives, solvents, plant ingredients, and other formulation components can contribute to irritation or allergic reactions.[4] Therefore, the reaction to a product containing peptides should be analyzed with respect to the entire formulation, and not automatically attributed to the peptide.
Can the data on the safety of topical and injectable preparations be used interchangeably?
No. Preparations applied to the skin and administered in other ways encounter different biological barriers and may lead to very different systemic exposure. They also differ in formulation and quality requirements. A small study on the tolerance of a local preparation does not confirm the systemic safety of another route of administration. [3] [10]
Can peptides interact with other medications?
Some specific peptide drugs can interact with other medications, but these are characteristics of individual products. Information regarding bremelanotide includes, for example, its effect on stomach emptying and the absorption of certain oral medications.[5] Interactions should therefore be checked for each specific intervention, rather than assuming them based on the mere inclusion in a broad category of peptides.
Is the medicinal product that has been placed on the market free from serious risk?
No. Marketing approval means assessing the benefits and risks in specific applications, not the absence of adverse effects. Clinical studies of drugs such as tirzepatide report adverse effects and cases of discontinuation of treatment in parallel with efficacy results.[2] Current warnings, contraindications, and precautions therefore remain relevant even after the drug has been approved for marketing.
Does the reassuring study in pregnancy confirm full safety?
No. A prospective cohort regarding exposure to GLP-1 receptor agonists in early pregnancy provided useful, reassuring data regarding the analyzed outcomes, but the sample size and the observational nature of the study left uncertainty. [12] Such results should be interpreted with respect to the specific molecules, the exposure period, the population, and the endpoints analyzed.
Does the absence of the substance in female milk mean safety for every breastfed child?
No. Unreliability depends, among other things, on the method used, the time of sample collection, the sampling method, and the detection limit. The study of semaglutide included eight women and left unanswered questions regarding long-term outcomes. [13] The result provides useful information about the samples examined, but does not confirm the full safety for every infant, every formulation, or every stage of lactation.
Does a long open study that is extended remove all doubts regarding safety?
No. Longer-term follow-up can provide additional information, but studies that are extended may be subject to selection and loss of participants. People who tolerate the earlier part of the study well are more likely to continue participation. In the prolonged study of bremelanotide, initially 684 people participated, and 272 completed the additional follow-up period. [7] The absence of new safety signals is useful information, but it does not prove that rare or delayed events cannot occur.
Is the combination of several substances safe if each of them is tested separately?
This cannot be assumed. The combination of substances creates a new exposure situation. One component may affect the absorption or physiological action of the other, and separate studies may not even analyze the simultaneous use. Information regarding the interaction of bremelanotide shows that one intervention can change the exposure to another drug. [5] Therefore, separate data regarding each component do not automatically establish the safety of their combination.
What question is the most important when assessing the safety of a peptide?
The most useful question is: what evidence pertains to this molecule, the finished product, the route of exposure, the time of use, and the population we are talking about? Clinical studies, regulatory information, laboratory analyses, observational studies, and case reports provide different, complementary types of data. [1] [9] [10] A reliable assessment combines these sources, without assuming that natural origin, high purity, the „research use only” label, or the absence of data automatically confirm safety.
Data limitations regarding the safety of peptides
When assessing the safety of peptides, several important limitations regularly arise.
The first is the diversity of the entire class. Peptides differ significantly in sequence, biological target, pharmacology, formulation, and route of administration. Therefore, safety results for one molecule should not be automatically extrapolated to another.
The second limitation is the observation time. In many studies, participants are observed for weeks or months, not years. This limits the ability to detect delayed effects.
The third is the sample size. Small studies may well describe common tolerance-related problems, while remaining too small to reliably detect rare adverse effects.
The fourth limitation is population selection. Clinical trials often exclude people with certain diseases, those taking certain medications, pregnant women, breastfeeding women, or participants with other risk-increasing characteristics. Therefore, good tolerability in the studied group does not necessarily describe the population excluded.
The fifth problem is the product's specificity. In clinical trials, a precisely defined product is usually used. Unverified commercial products may differ in identity, amount of active substance, purity, microbiological quality, stability, or formulation.[9]
The sixth limitation is the separation of analytical tests. Identity, quantity, purity, microbiological quality, endotoxin levels, and stability are relevant to different questions. A good result in one category does not confirm all the other quality parameters.
The seventh problem is the uncertainty regarding causality. An adverse event occurring after exposure does not automatically mean that it was caused by it, especially outside controlled studies.
Finally, the absence of evidence should not be interpreted as either a guarantee of safety or an alarmist claim of harm. If there is a lack of adequate data on human safety, the scientifically appropriate conclusion is that the risk remains insufficiently characterized.
Summary
There is no single profile of side effects common to all peptides.
Safety depends on the specific molecule, the biological target, the formulation, the route of administration, the size and duration of exposure, the population being studied, the interactions, and the quality of the finished product.
Well-controlled studies show this diversity.
In studies with bremelanotide, nausea, skin redness, and headache were among the significant adverse reactions occurring more frequently than with placebo. [1] Studies with tirzepatide showed a different profile, dominated primarily by gastrointestinal adverse reactions. [2] In a small, 12-week study with a local tetrapeptide, no adverse reactions were reported. [3]
These results are not contradictory.
They concern various interventions.
Product quality constitutes an additional, independent layer of safety. A study of semaglutide products purchased online revealed discrepancies between the declared and measured amounts of the substance and the presence of endotoxins in the analyzed samples. [9] These results indicate possible quality issues, but do not indicate their frequency across the market.
Similarly, purity, identity, quantity, microbiological quality, endotoxins, and stability are separate analytical issues. A positive result from one test does not answer all the remaining questions.
Especially vulnerable populations require additional caution, because data obtained in healthy adults may not describe the risk during pregnancy, breastfeeding, childhood, advanced age, with significant co-morbid diseases, or when using multiple medications.[12][13]
The most reliable conclusion regarding safety is therefore specific, not general.
It should specify which substance was tested, what formulation and route of administration were used, who received it, how long the observation was conducted, what adverse effects occurred, which comparator was used, what quality data on the product are available, and what is still unknown.
Natural origin does not prove safety.
Regulatory approval does not mean zero risk.
A high percentage of purity does not confirm all aspects of the product's quality.
The term „research use only” does not indicate its suitability for use in humans.
The absence of adverse effects in a small study does not mean that there is zero risk.
On the other hand, the safety signal regarding a specific molecule and population does not prove that all peptides are associated with the same risk.
Peptide safety is therefore best analyzed separately for each molecule, formulation, exposure route, population, and set of available evidence.
Disclaimer
The article is purely educational and scientifically informative in nature. It does not constitute medical advice, diagnosis, information regarding the prescribing of medications, recommendations regarding dosage, instructions for administration, certification of product quality, or recommendations for the use of any peptide, drug, experimental compound, cosmetic product, or research product.
The safety data discussed refer to specific substances, formulations, exposure routes, populations, duration of exposure, and the conditions of individual studies. Adverse effects observed with a single peptide or peptide-related interventions should not be automatically extrapolated to other substances. At the same time, the absence of observed adverse effects in a small or short-term study should not be interpreted as evidence of zero risk.
Product identity, purity, substance quantity, sterility, endotoxin levels, stability, and clinical safety are separate issues and may require different types of evidence. Suspected adverse effects, drug interactions, exposure during pregnancy or breastfeeding, concomitant illness, or concerns regarding a specific product require an assessment based on actual exposure and individual clinical circumstances.
References
- Kingsberg, S. A., Clayton, A. H., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Simon, J. A. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: Two randomized phase 3 trials. Obstetrics and gynecology, 134(5), 899–908. https://doi.org/10.1097/AOG.0000000000003500
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. The New England journal of medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Lee, S. G., Kang, S. M., & Kang, H. (2024). Reduction of wrinkles using tetrapeptide-68 contained in an O/W formulation: A randomized double-blind placebo-controlled study. Pharmaceutics, 16(8), 987. https://doi.org/10.3390/pharmaceutics16080987
- U.S. Food and Drug Administration (n.d.). Allergens in cosmetics. Retrieved September 20, 2026, from Allergens in cosmetics
- Cosette Pharmaceuticals, Inc. (2025). Vyleesi—bremelanotide injection [Prescribing information]. DailyMed. Vyleesi—bremelanotide injection [Prescribing information]
- Herbst, K. L., Coviello, A. D., Page, S., Amory, J. K., Anawalt, B. D., & Bremner, W. J. (2004). A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. The Journal of clinical endocrinology and metabolism, 89(12), 5959–5965. https://doi.org/10.1210/jc.2003-032123
- Simon, J. A., Kingsberg, S. A., Portman, D., Williams, L. A., Krop, J., Jordan, R., Lucas, J., & Clayton, A. H. (2019). Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstetrics and gynecology, 134(5), 909–917. https://doi.org/10.1097/AOG.0000000000003514
- Adunsky, A., Chandler, J., Heyden, N., Lutkiewicz, J., Scott, B. B., Berd, Y., Liu, N., & Papanicolaou, D. A. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics, 53(2), 183–189. https://doi.org/10.1016/j.archger.2010.10.004
- Ashraf, A. R., Mackey, T. K., Vida, R. G., Kulcsár, G., Schmidt, J., Balázs, O., Domián, B. M., Li, J., Csákó, I., & Fittler, A. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: Market surveillance, content analysis, and product purchase evaluation study. Journal of medical Internet research, 26, e65440. https://doi.org/10.2196/65440
- U.S. Food and Drug Administration (n.d.). Certain bulk drug substances for use in compounding that may present significant safety risks. Retrieved September 20, 2026, from Certain bulk drug substances for use in compounding that may present significant safety risks
- U.S. Food and Drug Administration (n.d.). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved September 20, 2026, from FDA’s concerns with unapproved GLP-1 drugs used for weight loss
- Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., Diezi, L., Haefliger, D., Simões-Wüst, A. P., Addor, M. C., Baud, D., Lamine, F., Panchaud, A., Buclin, T., Girardin, F. R., & Winterfeld, U. (2024). Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ open, 14(4), e083550. https://doi.org/10.1136/bmjopen-2023-083550
- Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J., & Krutsch, K. (2024). Subcutaneous semaglutide during breastfeeding: Infant safety regarding drug transfer into human milk. Nutrients, 16(17), 2886. https://doi.org/10.3390/nu16172886